SCHEDULE: Phibro Animal Health Insider Adopts 10b5-1 Sales Plan

BFI Co., LLC and Jack C. Bendheim have established a Rule 10b5-1 trading plan to sell up to 750,000 shares of Phibro Animal Health Class A Common Stock.

Summary

• BFI Co., LLC, managed by Jack C. Bendheim, entered into a Rule 10b5-1 sales plan on May 20, 2026.
• The plan authorizes the sale of up to 750,000 shares of Class A Common Stock through March 17, 2027.
• The reporting persons currently beneficially own 19,552,186 shares, representing 48.2% of the total outstanding Class A Common Stock (assuming conversion of Class B shares).
• The sales plan is intended to facilitate portfolio diversification over an extended period.
• The first possible trade date under the new plan is September 16, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it represents insider selling, the use of a 10b5-1 plan is a standard, non-discretionary mechanism for portfolio diversification.

Positives

• The use of a Rule 10b5-1 plan provides a transparent, pre-scheduled mechanism for share sales, reducing potential market volatility associated with insider selling.
• The reporting persons maintain a significant ownership stake of 48.2%, signaling continued long-term alignment with the company.

Negatives

• The adoption of a sales plan indicates a planned reduction in the major shareholder's equity position in the company.

Risks

• The sales plan is subject to termination upon various events, including legal non-compliance, bankruptcy, or changes in the company's listing status.
• The concentration of ownership (48.2%) by the reporting persons remains a factor for minority shareholders.

Future Outlook

The reporting persons intend to diversify their investment portfolio through the systematic sale of up to 750,000 shares over the next ten months, while maintaining a substantial majority interest in the company.

Management Comments

• The Sales Plan was adopted to enable BFI to sell a modest portion of its shares of Class A Common Stock to diversify its investment portfolio over an extended period of time.

Industry Context

StockSavvy.ai notes that the adoption of 10b5-1 plans by major shareholders in the animal health sector is a standard corporate governance practice used to manage liquidity while avoiding accusations of trading on material non-public information.

Comparison to Industry Standards

• The use of 10b5-1 plans is consistent with best practices for major shareholders at companies like Zoetis or Elanco, providing a structured approach to divestment.
• The 48.2% ownership stake remains high compared to typical institutional holdings, reflecting the company's history as a family-influenced entity.

Corporate Governance

Stakeholder Impact

• Shareholders may see increased liquidity in the stock as shares are sold under the plan.
• The reduction in the reporting persons' stake is gradual and unlikely to impact control of the company.

Next Steps

• Commencement of sales under the Rule 10b5-1 plan starting September 16, 2026.
• Ongoing evaluation of investment alternatives by the reporting persons.

Key Dates

Keywords

Phibro Animal Health, PAHC, 10b5-1, Insider Trading, Schedule 13D, Jack Bendheim, BFI Co LLC